- Home
- SRZN vs VOR Comparison
SRZN vs VOR Comparison
Compare SRZN & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- VOR
- Stock Information
- Founded
- SRZN 2015
- VOR 2015
- Country
- SRZN United States
- VOR United States
- Employees
- SRZN N/A
- VOR N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- VOR Health Care
- Exchange
- SRZN Nasdaq
- VOR Nasdaq
- Market Cap
- SRZN 82.8M
- VOR 85.7M
- IPO Year
- SRZN N/A
- VOR 2021
- Fundamental
- Price
- SRZN $7.10
- VOR $0.18
- Analyst Decision
- SRZN Strong Buy
- VOR Buy
- Analyst Count
- SRZN 2
- VOR 7
- Target Price
- SRZN $38.50
- VOR $7.83
- AVG Volume (30 Days)
- SRZN 11.0K
- VOR 4.6M
- Earning Date
- SRZN 05-09-2025
- VOR 05-27-2025
- Dividend Yield
- SRZN N/A
- VOR N/A
- EPS Growth
- SRZN N/A
- VOR N/A
- EPS
- SRZN N/A
- VOR N/A
- Revenue
- SRZN $11,638,000.00
- VOR N/A
- Revenue This Year
- SRZN N/A
- VOR N/A
- Revenue Next Year
- SRZN N/A
- VOR N/A
- P/E Ratio
- SRZN N/A
- VOR N/A
- Revenue Growth
- SRZN N/A
- VOR N/A
- 52 Week Low
- SRZN $6.00
- VOR $0.15
- 52 Week High
- SRZN $18.17
- VOR $1.87
- Technical
- Relative Strength Index (RSI)
- SRZN 31.40
- VOR 19.39
- Support Level
- SRZN $9.96
- VOR $0.15
- Resistance Level
- SRZN $11.56
- VOR $0.27
- Average True Range (ATR)
- SRZN 0.96
- VOR 0.06
- MACD
- SRZN -0.29
- VOR -0.04
- Stochastic Oscillator
- SRZN 21.20
- VOR 8.00
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.